|
Temps réel estimé
18:26:51 28/08/2026
|
Varia. 5j.
|
Varia. 1 janv.
|
|
34,84 USD
|
-1,29%
|
 |
-5,53%
|
-2,93%
|
|
03/08 |
Indivior Pharmaceuticals, Inc. Enters into Senior Secured Term Loan Facility
| | |
03/08 |
Indivior Pharmaceuticals, Inc. Proposes Special Cash Dividend
| | |
03/08 |
Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Timothy C. Dec as Chief Financial Officer of Supernus, Inc
| | |
03/08 |
Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Jack A. Khattar as Chief Executive Officer of Supernus, Inc
| | |
03/08 |
Indivior Pharmaceuticals, Inc. Raises Earnings Guidance for the Fiscal Year 2026
| | |
03/08 |
Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Jack A. Khattar as Member of the Board of the Supernus, Inc
| | |
03/08 |
Indivior Pharmaceuticals, Inc. entered into a definitive agreement to acquire Supernus Pharmaceuticals, Inc. for $3.6 billion in a merger of equals transaction.
| | |
03/08 |
Indivior Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
| | |
03/08 |
Tranche Update on Indivior Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 26, 2026.
| | |
03/08 |
Supernus, Indivior merge to strengthen neuroscience drug portfolio
| | |
03/08 |
Supernus Pharmaceuticals, Indivior Pharmaceuticals to Merge in All-Stock Deal
| | |
03/08 |
Indivior Pharmaceuticals, Supernus Pharmaceuticals to Combine in All-Stock Merger
| | |
03/08 |
Indivior Pharmaceuticals Q2 Non-GAAP Earnings, Revenue Rise; 2026 Sales Outlook Upgraded
| | |
03/08 |
(INDV) Indivior Expects 2026 Net Revenue Range $1.30B - $1.37B, vs. FactSet Est of $1.26B
| | |
03/08 |
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Reports Q2 Revenue $343.0M, vs. FactSet Est of $307.6M
| | |
03/08 |
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $1.15 per Share, vs. FactSet Est of $0.89
| | |
30/07 |
Indivior Pharmaceuticals : Half a Million Reasons to Hope
| | |
29/06 |
Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Value-Defensive Index
| | |
29/06 |
Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Growth-Defensive Index
| | |
29/06 |
Indivior Pharmaceuticals, Inc.(NasdaqGS:INDV) added to Russell 2000 Defensive Index
| | |
10/06 |
Indivior Pharmaceuticals Insider Sold Shares Worth $1,357,200, According to a Recent SEC Filing
| | |
21/05 |
Indivior Pharmaceuticals - New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
| | |
20/05 |
Indivior Pharmaceuticals Announces Findings From Real-World Evidence Studies on Monthly Injectable Buprenorphine
| | |
04/05 |
Indivior Pharmaceuticals Enters $175 Million Accelerated Share Repurchase Agreement
| | |
30/04 |
Tranche Update on Indivior Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 26, 2026.
| |
Aucun résultat pour cette recherche Sélectionnez votre édition Toutes les informations financières adaptées au niveau national | 
